Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis...
35 KB (3,270 words) - 07:00, 28 August 2024
been explored, including immunomodulatory agents such as imiquimod. Tofacitinib citrate may also have benefits. In June 2014, a 25-year-old man with...
11 KB (1,130 words) - 01:31, 18 June 2024
transcription. The first JAK inhibitor to reach clinical trials was tofacitinib. Tofacitinib is a specific inhibitor of JAK3 (IC50 = 2 nM) thereby blocking...
36 KB (3,044 words) - 22:30, 11 September 2024
gene expression in immunological cells. Other JAK inhibitors include tofacitinib, which is indicated for the treatment of rheumatoid arthritis, psoriatic...
43 KB (3,613 words) - 02:13, 16 July 2024
colitis, myeloid metaplasia with myelofibrosis and vitiligo. Examples are tofacitinib, baricitinib, upadacitinib and filgotinib. In 2014 researchers discovered...
9 KB (974 words) - 14:46, 22 June 2024
current generic equivalent available on the market. The JAK1 inhibitors tofacitinib (Xeljanz) and upadacitinib (Rinvoq) are approved for the use in active...
32 KB (3,438 words) - 14:55, 9 July 2024
neratinib, eltrombopag, ibrutinib, lenvatinib, palbociclib, regorafenib, tofacitinib, and trelagliptin. BEACON Medicare Limited(BML) is the exclusive global...
5 KB (232 words) - 10:23, 8 March 2024
The US Food and Drug Administration (FDA) requires a boxed warning for tofacitinib, baricitinib, and upadacitinib to include information about the risks...
46 KB (4,534 words) - 22:58, 20 August 2024
upadacitinib.[medical citation needed] Less selective JAK inhibitors (e.g. tofacitinib and baricitinib) are already being marketed.[medical citation needed]...
24 KB (2,250 words) - 06:06, 16 July 2024
combination with either methotrexate or leflunomide. Biologic monotherapy or tofacitinib with methotrexate may improve ACR50, RA remission rates and function...
147 KB (15,992 words) - 01:02, 12 September 2024
Ruxolitinib SD-1008 Tofacitinib (tasocitinib) JAK3 Cercosporamide Decernotinib (VX-509) Peficitinib Ritlecitinib TCS-21311 Tofacitinib (tasocitinib) WHI-P...
26 KB (2,188 words) - 05:17, 13 June 2024
Ruxolitinib SD-1008 Tofacitinib (tasocitinib) JAK3 Cercosporamide Decernotinib (VX-509) Peficitinib Ritlecitinib TCS-21311 Tofacitinib (tasocitinib) WHI-P...
33 KB (3,686 words) - 07:30, 20 May 2024
Kotb A, Christensen R, Mudano AS, et al. (May 2016). "Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or...
24 KB (2,070 words) - 07:13, 15 March 2024
Ruxolitinib SD-1008 Tofacitinib (tasocitinib) JAK3 Cercosporamide Decernotinib (VX-509) Peficitinib Ritlecitinib TCS-21311 Tofacitinib (tasocitinib) WHI-P...
33 KB (2,917 words) - 16:32, 16 July 2024
rheumatoid arthritis was tofacitinib. It has also shown promising results in other autoimmune disorders. Initially, tofacitinib was thought to be a selective...
17 KB (2,126 words) - 15:12, 16 June 2024
Ruxolitinib SD-1008 Tofacitinib (tasocitinib) JAK3 Cercosporamide Decernotinib (VX-509) Peficitinib Ritlecitinib TCS-21311 Tofacitinib (tasocitinib) WHI-P...
23 KB (2,087 words) - 09:12, 24 August 2024
Ruxolitinib SD-1008 Tofacitinib (tasocitinib) JAK3 Cercosporamide Decernotinib (VX-509) Peficitinib Ritlecitinib TCS-21311 Tofacitinib (tasocitinib) WHI-P...
31 KB (3,430 words) - 05:24, 28 August 2024
surgery, hospitalization, pregnancy, the use of corticosteroids and tofacitinib, a JAK inhibitor. Osteoporosis may occur related to systemic inflammation...
142 KB (16,184 words) - 05:34, 13 September 2024
for the treatment of eczema and dermatitis. Delgocitinib Izencitinib Tofacitinib Raghuvanshi R, Bharate SB (January 2022). "Recent Developments in the...
3 KB (246 words) - 20:24, 22 June 2024
vitiligo and other skin diseases. A medication for rheumatoid arthritis, tofacitinib, has been tested for the treatment of vitiligo. In October 1992, a scientific...
42 KB (4,377 words) - 22:58, 6 September 2024
with reduced side effects compared to other similar drugs. Delgocitinib Tofacitinib Roda G, Dal Buono A, Argollo M, Danese S (September 2020). "JAK selectivity:...
2 KB (153 words) - 20:24, 22 June 2024
Ruxolitinib SD-1008 Tofacitinib (tasocitinib) JAK3 Cercosporamide Decernotinib (VX-509) Peficitinib Ritlecitinib TCS-21311 Tofacitinib (tasocitinib) WHI-P...
13 KB (1,176 words) - 21:00, 10 July 2024
availability of TNF inhibitors and other agents, such as tocilizumab and tofacitinib. Penicillamine works by reducing numbers of T-lymphocytes, inhibiting...
16 KB (1,389 words) - 02:48, 13 September 2024
Ruxolitinib SD-1008 Tofacitinib (tasocitinib) JAK3 Cercosporamide Decernotinib (VX-509) Peficitinib Ritlecitinib TCS-21311 Tofacitinib (tasocitinib) WHI-P...
25 KB (2,344 words) - 01:12, 1 September 2024
foundation of targeted therapy. Janus kinase inhibitors, e.g. FDA approved tofacitinib ALK inhibitors, e.g. crizotinib Bcl-2 inhibitors (e.g. FDA approved venetoclax...
20 KB (2,234 words) - 01:21, 22 July 2024
Ruxolitinib SD-1008 Tofacitinib (tasocitinib) JAK3 Cercosporamide Decernotinib (VX-509) Peficitinib Ritlecitinib TCS-21311 Tofacitinib (tasocitinib) WHI-P...
9 KB (457 words) - 08:58, 6 August 2024
recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate". Journal of the American Academy of Dermatology. 73 (3): 395–9...
10 KB (899 words) - 00:28, 17 July 2024
received approval from the Food and Drug Administration for Xeljanz, a tofacitinib, for rheumatoid arthritis and ulcerative colitis. The drug had sales...
167 KB (14,521 words) - 00:40, 7 September 2024
Ruxolitinib SD-1008 Tofacitinib (tasocitinib) JAK3 Cercosporamide Decernotinib (VX-509) Peficitinib Ritlecitinib TCS-21311 Tofacitinib (tasocitinib) WHI-P...
26 KB (2,102 words) - 02:19, 16 July 2024
Ruxolitinib SD-1008 Tofacitinib (tasocitinib) JAK3 Cercosporamide Decernotinib (VX-509) Peficitinib Ritlecitinib TCS-21311 Tofacitinib (tasocitinib) WHI-P...
24 KB (2,932 words) - 03:26, 14 June 2024